Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...
Long-term investments in top tech, health, and consumer staples for stability, growth, and reliable returns. Read what ...
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...
Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Manufacturers of medicines, including Pfizer and Eli Lilly, have spent a combined $450,000 lobbying against price caps on ...
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...
When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...
A new study led by researchers from Boston University Chobanian & Avedisian School of Medicine has found there is no consensus in how clinical experts interpret CGM reports from people without ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results